Zoetis ZTS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| International | $4.4B+3.9% | $4.23B+2.0% | $4.15B+0.8% | $4.12B+0.9% | $4.08B-0.5% | |
| U.S. | $5B-1.8% | $5.1B-0.4% | $5.12B-0.5% | $5.14B+0.9% | $5.09B+0.4% | |
| Revenue by Product | ||||||
| Animal health diagnostics | $448M+3.0% | $435M+2.6% | $424M+2.2% | $415M+1.7% | $408M+5.7% | |
| Anti-infectives | $1.03B+0.3% | $1.03B+0.3% | $1.02B+1.0% | $1.01B-4.3% | $1.06B-3.9% | |
| Cattle | $1.53B+3.5% | $1.48B+1.1% | $1.46B+0.6% | $1.45B-2.0% | $1.48B-3.3% | |
| Contract manufacturing & human health | $110M-6.0% | $117M+8.3% | $108M+1.9% | $106M+17.8% | $90M+12.5% | |
| Dermatology | $1.71B-1.7% | $1.74B+0.5% | $1.74B+1.1% | $1.72B+2.7% | $1.67B+1.0% | |
| Fish | $299M+3.8% | $288M+5.9% | $272M+3.0% | $264M+4.8% | $252M+4.1% | |
| Horses | $6.29B+0.2% | $6.28B+4.6% | $6B+0.1% | $6B+0.1% | $5.99B0.0% | |
| Other Non Pharmaceuticals | $263M-1.9% | $268M+1.9% | $263M+0.8% | $261M-0.8% | $263M+4.0% | |
| Other pharmaceutical | $696M0.0% | $696M+1.2% | $688M+1.3% | $679M+2.9% | $660M+0.3% | |
| Pain and sedation | $833M-0.5% | $837M-0.9% | $845M-1.7% | $860M-0.5% | $864M+1.5% | |
| Parasiticides | $2.37B+0.6% | $2.35B+1.0% | $2.33B+1.5% | $2.29B+3.3% | $2.22B+3.2% | |
| Poultry | $444M+2.8% | $432M0.0% | $432M-7.1% | $465M-5.9% | $494M-6.3% | |
| Sheep and other | $92M+1.1% | $91M+1.1% | $90M+4.7% | $86M+2.4% | $84M+2.4% | |
| Swine | $478M+3.9% | $460M-0.6% | $463M-4.1% | $483M-2.2% | $494M-4.3% | |
| Vaccines | $2.03B+4.1% | $1.95B+2.6% | $1.9B+1.5% | $1.87B+3.3% | $1.81B-0.7% | |
| Revenue by Geography | ||||||
| Australia | $343M+3.0% | $333M+1.2% | $329M+1.2% | $325M0.0% | $325M+1.9% | |
| Brazil | $395M+2.3% | $386M-0.3% | $387M-0.3% | $388M-1.5% | $394M-4.8% | |
| Canada | $296M+1.0% | $293M+1.7% | $288M+1.4% | $284M-0.7% | $286M+3.2% | |
| Chile | $143M+2.1% | $140M+7.7% | $130M-1.5% | $132M+3.9% | $127M+3.3% | |
| China | $230M+3.6% | $222M-6.3% | $237M-6.3% | $253M+1.6% | $249M-7.8% | |
| France | $162M-1.2% | $164M+4.5% | $157M+2.6% | $153M-0.6% | $154M-1.3% | |
| Germany | $244M+1.7% | $240M+2.6% | $234M+2.2% | $229M0.0% | $229M+1.8% | |
| Italy | $147M+6.5% | $138M+0.7% | $137M+3.0% | $133M+1.5% | $131M+1.6% | |
| Japan | $153M+2.0% | $150M+0.7% | $149M+0.7% | $148M+4.2% | $142M-3.4% | |
| Mexico | $171M+8.2% | $158M+2.6% | $154M+1.3% | $152M-5.0% | $160M-5.3% | |
| Other developed markets | $677M+5.6% | $641M+5.1% | $610M+2.7% | $594M+4.2% | $570M+1.1% | |
| Other emerging markets | $956M+5.9% | $903M+1.9% | $886M+0.9% | $878M+0.3% | $875M+1.2% | |
| Spain | $152M+7.8% | $141M+5.2% | $134M+2.3% | $131M+3.1% | $127M-2.3% | |
| Total geographical area | $9.4B+0.8% | $9.33B+0.7% | $9.27B+0.1% | $9.26B+0.9% | $9.17B0.0% | |
| United Kingdom | $326M+1.2% | $322M+1.6% | $317M+0.6% | $315M+1.3% | $311M-1.0% | |
| United States | $5B-1.8% | $5.1B-0.4% | $5.12B-0.5% | $5.14B+0.9% | $5.09B+0.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zoetis break its business down?
- Zoetis (ZTS) reports revenue by business across 2 parts — International and U.S.. Each is extracted from the segment footnotes and tracked over time.
- Where does Zoetis's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zoetis's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
